Valuation: AC Immune SA

Market Cap 216M 260M 228M 196M 368M 24.91B 370M 2.58B 998M 12.71B 974M 953M 40.85B P/E 2026 *
-5.25x
P/E 2027 * 11.2x
Enterprise Value 171M 206M 181M 155M 291M 19.74B 293M 2.05B 791M 10.07B 772M 755M 32.37B EV / Sales 2026 *
9.16x
EV / Sales 2027 * 2.61x
Free-Float
56.14%
Yield 2026 *
-
Yield 2027 * -
1 day+3.57%
1 week-1.69%
Current month-1.14%
1 month-1.51%
3 months+1.95%
6 months-3.33%
Current year-16.88%
1 week 2.4
Extreme 2.405
2.91
1 month 2.4
Extreme 2.405
3
Current year 2.1
Extreme 2.095
3.9
1 year 2.1
Extreme 2.095
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
8.14
10 years 1.43
Extreme 1.4299
18.95
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Director/Board Member 65 2021-10-28
Date Insider Type Main position Quantity % Market Cap. Importance
5/15/26 Sell

Founder

-10,000 0.0098%
4/15/26 Sell

Founder

10,000 0.0101%
3/20/26 Other

Chief Operating Officer

520,081 0.5256%
Change 5-day change 1-year change 3-year change Capi.($)
+3.57%-1.69%-8.10%-10.00% 251M
-0.80%+14.07%+705.55%+96.75% 79.4B
-4.54%-5.75%+33.40%-9.86% 78.69B
-0.04%+0.61%-8.64%-27.51% 59.52B
-0.89%+0.19%+7.92%+172.79% 46.58B
+2.49%-0.14%-8.95%+33.71% 46.53B
+0.48%+4.39%+66.48%-11.30% 33.63B
+0.75%+0.14%+50.93%+112.97% 25.11B
-0.57%-7.32%+2.08%+149.80% 22.13B
+0.73%-0.95%+61.19%+97.04% 15.31B
Average +0.21%+1.30%+90.19%+60.44% 40.71B
Weighted average by Cap. -0.59%+2.24%+153.71%+54.38%

Financials

2026 *2027 *
Net sales 18.66M 22.44M 19.74M 16.93M 31.79M 2.15B 31.98M 223M 86.31M 1.1B 84.26M 82.43M 3.53B 89.19M 107M 94.32M 80.9M 152M 10.29B 153M 1.07B 412M 5.25B 403M 394M 16.88B
Net income -42.87M -51.55M -45.34M -38.89M -73.03M -4.95B -73.45M -513M -198M -2.53B -194M -189M -8.11B 19.95M 23.99M 21.1M 18.1M 33.99M 2.3B 34.19M 239M 92.27M 1.18B 90.08M 88.13M 3.78B
Net Debt -44.8M -53.87M -47.38M -40.63M -76.31M -5.17B -76.76M -536M -207M -2.64B -202M -198M -8.48B 17.1M 20.56M 18.08M 15.51M 29.13M 1.97B 29.3M 205M 79.07M 1.01B 77.19M 75.52M 3.24B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-09-28 US$2.610 +3.57% 188,867
26-09-25 US$2.520 -5.26% 323,580
26-09-24 US$2.660 -6.01% 265,287
26-09-23 US$2.830 +3.66% 492,823
26-09-22 US$2.730 +2.82% 78,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.171CHF
Average target price
7.095CHF
Spread / Average Target
+226.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock